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Abstract 
Objective: Registries are important data sources for randomized controlled trials (RCTs), but reporting of how they are used may 
be inadequate. The objective was to describe the current adequacy of reporting of RCTs using registries. 
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Study Design and Setting: We used a database of trials using registries from a scoping review supporting the development of 
the 2021 CONSORT extension for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE). Reporting 
completeness of 13 CONSORT-ROUTINE items was assessed. 
Results: We assessed reports of 47 RCTs that used a registry, published between 2011 and 2018. Of the 13 CONSORT-ROUTINE 
items, 6 were adequately reported in at least half of reports (2 in at least 80%). The 7 other items were related to routinely collected 
data source eligibility (32% adequate), data linkage (8% adequate), validation and completeness of data used for outcome assessment 
(8% adequate), validation and completeness of data used for participant recruitment (0% adequate), participant flow (9% adequate), 
registry funding (6% adequate) and interpretation of results in consideration of registry use (25% adequate). 
Conclusion: Reporting of trials using registries was often poor, particularly details on data linkage and quality. Better reporting is 
needed for appropriate interpretation of the results of these trials. © 2021 The Authors. Published by Elsevier Inc. This is an open 
access article under the CC BY license ( http:// creativecommons.org/ licenses/ by/ 4.0/ ) 
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What is new? 
• Adequate reporting of essential features of random- 
ized trials is critical but often inadequate in biomed- 
ical journals. 
• The reporting of randomized trials using registries 
was inadequate for several critical details that are 
required for replication, bias assessment, interpre- 
tation and application of trial results. 
• This study highlights an even lower reporting qual- 
ity for registry-specific reporting items compared to 





















































Registries are repositories of health information with
those registered sharing a common characteristic, such as
a disease, a drug treatment or health exposure [1] . They
can be used to monitor the progression of a health condi-
tion and are often utilized to explore etiology, progression
and potential treatments or cures of diseases and adherence
to treatment guidelines. Registries are a type of routinely
collected data that are increasingly utilized as a frame-
work to support randomized controlled trials (RCTs) [2–
4] . Compared to traditional RCTs, which are dependent on
primary data collection within the trial, RCTs conducted
using routinely collected data, including registries, may al-
low the exploration of pragmatic questions in so called
“real world settings,” potentially increasing the applicabil-
ity of the results [5] . Traditional RCTs are often expen-
sive, particularly due to the costs of setting up a specific
research and data collection infrastructure; leveraging the
environment of a registry may greatly reduce expenditures
associated with assessing a novel treatment or choosing the
best among alternative treatment choices [6] . Nonetheless,
designing and maintaining registries is itself expensive, and
access to the registry data can have costs [7–9] . Please cite this article as: K.A. Mc Cord et al., Reporting transparency and 
registries was often inadequate and hindered the interpretation of results, JournalThe use of routinely collected data to conduct trials is
a novel approach and requires reporting of elements that
are not part of traditional RCTs. This extra reporting facili-
tates replication and assessment of biases and applicability.
For example, consent processes may be different from and
more diverse than in traditional trials, and the complete-
ness and accuracy of data that were not collected for the
purpose of a specific trial may require special consider-
ation. The advantage of potentially better applicability of
findings from such trials may be lost if there is a mismatch
between key aspects of participants in the data source in
relation to a target population [10] , but for an assessment
of this, there must be adequate and complete reporting
needs. 
Traditional RCTs are often reported inadequately, [11]
and with the added complexity in new trial designs using
routinely collected data, reporting challenges may increase.
To address the novel reporting needs of trials conducted
using routinely collected data, an extension of the Con-
solidated Standards of Reporting Trials (CONSORT) 2010
guideline [12] for the reporting of RCTs conducted using
cohorts and routinely collected data has been developed
and published in 2021 (CONSORT-ROUTINE) [13] . The
present study used reports of trials using registry data that
were identified in a scoping review informing our guideline
development process. 
We aimed to: (1) describe characteristics of RCTs con-
ducted using registry data and published after the CON-
SORT 2010 statement; and (2) assess and describe the
quality of reporting of the trials’ reports in peer-reviewed
journals. Similar analyses for trials using electronic health
records (EHRs) [14] and administrative databases [15] are
reported elsewhere. 
2. Methods 
A protocol for this study was made publicly available
in the Open Science Framework: https:// osf.io/ x75gf/ . completeness in Trials: Paper 2 - reporting of randomised trials using 
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2.1. Inclusion and exclusion criteria for RCTs using 
registries 
Reports of trials that utilized registries to select pa-
tients or ascertain outcomes in any way were included in
the present study. Thus, we included RCTs that utilized
registries as a supporting data source, as well as RCTs
fully embedded within a registry framework (registry-based
RCTs). Although RCTs using registries as an interven-
tion were also eligible for inclusion, we identified no such
trials in our literature search as this is typically a fea-
ture of trials using EHRs. Our definition of registry was
based on that of the European Medicines Agency and
the Clinical Trials Transformation Initiative as “an orga-
nized system that uses observational methods to collect
uniform data on specified outcomes in a population de-
fined by a particular disease, condition, or exposure, and
that is followed over time.”[16] ; and “Entry in a reg-
istry is generally defined either by diagnosis of a dis-
ease (disease registry) or prescription of a drug, device,
or other treatment (exposure registry)” [17] (Appendix 1).
The main scoping review (see below) searched for publi-
cations from 2007 – 2018, but here we limited our sam-
ple to RCTs published after 2010, when the CONSORT
2010 statement was published. Methodological reviews,
commentaries, trial protocols, cost-effectiveness studies
or RCTs assessing non-health outcomes were excluded.
The detailed inclusion/exclusion criteria are shown in
Appendix 1. 
2.2. Search strategy and study selection 
A literature search was performed for the scoping re-
view in the framework of the CONSORT-ROUTINE [18] .
Briefly, the scoping review aimed to identify items impor-
tant for reporting by trials conducted using cohorts and
routinely collected data, including registries, EHRs, and
administrative data as well as to identify examples of good
reporting. The database search was designed and conducted
by an experienced research librarian (MS) familiar with
knowledge synthesis related to research methods and re-
porting with input from the project team and was peer
reviewed using the Peer Review of the Electronic Search
Strategy (PRESS) [19] . Databases were searched from Jan-
uary 2007 – March 2018 and included Ovid MEDLINE
Epub Ahead of Print, In-Process & Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily and Ovid MEDLINE and
EBM Reviews - Cochrane Methodology Registry (Final
issue, third Quarter 2012) (search strategy in Appendix
2). References were imported into RefWorks, and dupli-
cates were removed. References were then imported into
the systematic review software DistillerSR (Evidence Part-
ners, Ottawa, Canada) [20] . This literature search served
the purpose of identifying a representative sample of RCTs
using routinely collected data to inform the development
of the reporting guideline; it was not a complete assess-Please cite this article as: K.A. Mc Cord et al., Reporting transparency and c
registries was often inadequate and hindered the interpretation of results, Journalment of all the available published trials using routinely
collected data. 
Two reviewers independently screened the titles and
abstracts of publications in random order using a lib-
eral accelerated method, where titles and abstracts are
screened by one reviewer and only excluded publications
are screened by a second reviewer [21] . The random order
ensured that the reviewers were unaware about the other
reviewer’s decision on any given title and abstract. Two
reviewers then screened the full texts independently and
resolved any disagreements with discussion and consensus
(involving a third reviewer where necessary). 
2.3. Data extraction 
For all RCTs, two independent reviewers extracted data
from the full text reports on whether the registry was uti-
lized (1) to identify and recruit patients only, (2) to as-
certain outcomes only, (3) for both patient recruitment
and outcome assessment. Furthermore, we extracted the
RCTs’ characteristics (publication year, sample size, coun-
try of data collection, randomization type, registry use) and
PICO information (Population, Intervention, Comparator
and Outcome) ( Table 1 ). We also classified publications
into primary and secondary reports to evaluate any dif-
ferences in the quality of reporting. Primary publications
were reports on the trial’s primary patient outcome(s) and
may also report other trial outcomes Although secondary
publications were reports on only secondary patient out-
comes or other post-hoc outcomes (if a report referred to
a previous publication or did not specify outcome status
but referred to a previous publication of results, then the
report was categorized as secondary). Any disagreements
were resolved in consultation with a third reviewer. 
2.4. Evaluation of completeness and transparency of 
reporting 
Two independent reviewers assessed the reporting trans-
parency and completeness for all new and modified items
from the CONSORT-ROUTINE checklist. For the modified
items, we additionally performed the reporting assessment
for the CONSORT 2010 version in an attempt to distin-
guish potential poor reporting of the trials in general (and
according to the reporting standard at the time of publica-
tion of the included trial) from the modified portion. For
such pairs of original and modified items, we evaluated
separately the original item (as written) and, the modified
part. Reporting of items that remained unmodified from the
CONSORT 2010 statement were not assessed. Of note, a
reporting assessment was not performed separately for the
item on allocation concealment, as the modification was
a clarification of the original item related to the use of
routinely collected data. 
We defined the completeness of reporting as “Ade-
quately reported” when the reviewers could clearly identifyompleteness in Trials: Paper 2 - reporting of randomised trials using 
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Table 1. Characteristics of trials conducted using registries 
RCTs using registries for: 
PI only N (%) OA only N (%) PI and OA N (%) Total N (%) 
10 (28%) 23 (51%) 14 (21%) 47 (100%) 
Registry used for primary outcome 
ascertainment (versus no or unclear a ) 
0 (0%) 21 (91%) 12 (86%) 33 (70%) 
Publication type 
Primary 7 (70%) 14 (61%) 13 (93%) 34 (72%) 
Secondary 3 (30%) 9 (39%) 1 (7%) 13 (28%) 
Sample size 
(median [IQR]) 
737 [300-6846] 2029 [268-2774] 2722 [680-7736] 1826 [347-3618] 
Year 
(median [IQR]) 
2015 [2013-2016] 2015 [2013-2016] 2015 [2013-2017] 2015 [2013-2016] 
Setting 
Primary care 0 (0%) 3 (13%) 1 (7%) 4 (8%) 
Inpatient 1 (10%) 14 (61%) 4 (29%) 19 (40%) 
Outpatient 0 (0%) 1 (4%) 1 (7%) 2 (4%) 
Community medicine 9 (90%) 5 (22%) 8 (57%) 22 (47%) 
Country 
Scandinavia 1 (10%) 15 (65%) 5 (36%) 21 (45%) 
USA 4 (40%) 4 (17%) 4 (29%) 12 (25%) 
Continental Europe 3 (30%) 3 (13%) 1 (7%) 7 (15%) 
Australia 1 (10%) 0 (0%) 2 (14%) 3 (6%) 
UK 0 (0%) 0 (0%) 1 (7%) 1 (2%) 
Other b 1 (10%) 1 (4%) 1 (7%) 3 (6%) 
Medical specialty 
Cardiology - 12 (52%) 5 (36%) 17 (36%) 
Oncology 7 (70%) 2 (9%) 3 (21%) 12 (25%) 
Internal medicine 0 (0%) 3 (13%) 5 (36%) 8 (17%) 
Neurology/Psychiatry 1 (10%) 3 (13%) 1 (7%) 5 (11%) 
Pediatrics 1 (10%) 2 (9%) 0 (0%) 3 (6%) 
Other c 1 (10%) 1 (4%) 0 (0%) 2 (4%) 
Intervention 
Surgery 0 (0%) 10 (43%) 4 (29%) 14 (30%) 
Guideline/reminder 0 (0%) 2 (9%) 4 (29%) 6 (13%) 
Drug 1 (10%) 5 (22%) - 6 (13%) 
Screening 3 (30%) 1 (4%) 1 (7%) 5 (11%) 
Education/coaching 2 (20%) 3 (13%) 1 (7%) 6 (13%) 
Lifestyle 2 (20%) 1 (4%) 1 (7%) 4 (8%) 
Multiple 0 (0%) 1 (4%) 1 (7%) 2 (4%) 
Other d 2 (20%) 0 (0%) 2 (14%) 4 (8%) 
Comparator 
Usual care 8 (80%) 9 (39%) 12 (86%) 29 (62%) 
Active comparator 1 (10%) 11 (48%) 2 (14%) 14 (30%) 
Placebo 1 (10%) 3 (13%) 0 (0%) 4 (8%) 
Outcome 
Composite 0 (0%) 12 (52%) 1 (7%) 13 (28%) 
Disease occurrence/AE 1 (10%) 4 (17%) 1 (7%) 6 (13%) 
Mortality - 3 (13%) 4 (29%) 7 (15%) 
Self-reported 4 (40%) 0 (0%) 0 (0%) 4 (8%) 
( continued on next page ) 
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Table 1 ( continued ) 
RCTs using registries for: 
PI only N (%) OA only N (%) PI and OA N (%) Total N (%) 
Uptake of treatment 2 (20%) 2 (9%) 3 (21%) 7 (15%) 
Quality improvement 1 (10%) 0 (0%) 1 (7%) 2 (4%) 
Other e 2 (20%) 2 (8%) 4 (28%) 8 (17%) 
PI: Patient identification; OA: Outcome assessment; AE: adverse events; RCT: randomised controlled trial. 
a Unclear for one trial in ‘PI and OA’ category; Other includes: 
b Iran and Israel; 
c Intensive care and Nephrology; 
d Networking intervention, oxygen therapy, enhanced invitation letter and quality improvement; 
e Surrogate, Fatigue Impact Scale (FIS) score, letter response rate, minimum differences of interest (MDI) of weight loss, time to hospitalization 



























































the required details for each item in the RCT publication,
“Partially reported” when some of the details were clearly
identifiable by the reviewers in the publication (but not
all, if applicable) or if the information was implied but
not clearly stated by the authors, “Inadequately reported”
or “Not reported” when the reviewers could not identify
the required details for the item in the publication, and
“Not applicable” in cases where the reporting item was
not relevant to the trial (for example, if the RCT only
used the registry to ascertain outcomes, patient identifica-
tion or participant flow items would not be relevant). We
used a coding manual to ensure consistent assessment of
reporting (see Appendix 3) which was also used in related
studies on the completeness and transparency of reporting
in administrative databases and EHRs [14–15] . 
The CONSORT 2010 and extension items are widely
accepted as the minimum required information for each
RCT publication, therefore we did not search for additional
publications to complement missing information even if
the authors mentioned that such information was published
elsewhere. 
Any disagreements were resolved by consensus. Data
extraction was performed using Distiller SR by one inves-
tigator and validated by a second investigator using the
DistillerSR Quality Control function. 
2.5. Data analysis 
All data were reported as simple frequency statistics
such as absolute frequencies, medians and interquartile
ranges (IQRs). No formal test statistics were performed. 
3. Results 
3.1. Characteristics of included RCTs 
Of the 47 included publications ( Fig 1 ), 23 (51%)
described trials that used registries to assess outcomes
only, another 14 (21%) used them for both patient iden-
tification and outcome assessment and the remaining 10Please cite this article as: K.A. Mc Cord et al., Reporting transparency and c
registries was often inadequate and hindered the interpretation of results, Journal(28%) of them used it for patient identification only ( Ta-
ble 2 ). Thirty-four (72%) were primary publications, and
13 (28%) were secondary publications. 
The largest number of RCTs using registries were per-
formed in Scandinavian countries (21 of 47; 45%), fol-
lowed by the United States of America ( n = 12; 25%)
and Continental Europe ( n = 7; 15%) ( Table 2 ). The me-
dian sample size was 1826 participants [IQR 347-3618].
Five trials had a cluster design, and the median number of
participants per cluster was 136 [IQR 17-312]. The most
frequently researched medical specialties were cardiology
( n = 17; 36%), oncology ( n = 12; 25%) and internal
medicine ( n = 8; 17%). The interventions most frequently
tested were surgical or invasive procedures ( n = 14; 30%),
delivery of guidelines and reminders to clinicians ( n = 6;
13%) and drugs ( n = 6; 13%); although the comparators
were mostly usual care ( n = 29; 62%), active comparators
( n = 14; 30%) or placebo ( n = 4; 8%) ( Table 2 ). 
3.2. Baseline assessment of completeness and 
transparency of reporting 
CONSORT 2010 Items with Modifications in
CONSORT-ROUTINE 
Eight CONSORT 2010 items were modified in
CONSORT-ROUTINE . The CONSORT 2010 version of
these 6 of these items (“Structured summary,” “Trial de-
sign,” “Eligibility criteria,” “Outcome definition,” “Partic-
ipant flow” and “Interpretation”) were adequately reported
in over 90% of the trials. Details on “Allocation conceal-
ment mechanism” and “Funding” were reported adequately
in only 55% (26 of 47) and 68% (32 of 47) of the trials,
respectively ( Table 2 ). 
The modified portions of these items were adequately
reported in less than half of the trial reports, with the ex-
ception of mentioning the use of a cohort or routinely col-
lected data in the trial, which was typically adequately
stated in the abstract (40 of 47; 85%. The name and use
of a registry were almost always reported in the main textompleteness in Trials: Paper 2 - reporting of randomised trials using 





























































Table 2. Completeness and transparency of reporting for CONSORT 2010 items that were modified, modified items, and new items in CONSORT-ROUTINE a . 
Item b CONSORT 2010 Items, CONSORT-ROUTINE modifications, and new 
CONSORT-ROUTINE items 
















1b CONSORT 2010: Structured summary of trial design, methods, 
results, and conclusions (for specific guidance see CONSORT for 
abstracts). 
43 (91%) 4 (9%) 0 (0%) - 
Modified CONSORT-ROUTINE: Structured summary of trial 
design, methods, results, and conclusions (for specific guidance 
see CONSORT for abstracts). Specify that a cohort or routinely 
collected data were used to conduct the trial and, if applicable, 
provide the name of the cohort or routinely collected database(s) 
40 (85%) 1 (2%) 6 (13%) - 
Methods 
Trial design 3a CONSORT 2010: Description of trial design (such as parallel, 
factorial) including allocation ratio 
46 (98%) 0 (0%) 1 (2%) - 
Modified CONSORT-ROUTINE: Description of trial design (such 
as parallel, factorial) including allocation ratio, that a cohort or 
routinely collected database(s) was used to conduct the trial 
(such as electronic health record, registry) and how the data were 
used within the trial (such as identification of eligible trial 
participants, trial outcomes) 





ROUTINE-1 New CONSORT-ROUTINE: Name, if applicable, and description 
of the cohort or routinely collected database(s) used to conduct 
the trial, including information on the setting (such as primary 
care), locations, and dates, (such as periods of recruitment, 
follow-up, and data collection) 
24 (51%) 21 
(45%) 
2 (4%) - 
ROUTINE-2 New CONSORT-ROUTINE: Eligibility criteria for participants in 
the cohort or routinely collected database(s) 
15 (32%) 15 
(32%) 
17 (36%) - 
ROUTINE-3 New CONSORT-ROUTINE: State whether the study included 
person-level, institutional-level, or other data linkage across two 
or more databases and, if so, linkage techniques and methods 
used to evaluate completeness and accuracy of linkage 
4 (8%) 15 
(32%) 
28 (60%) - 
Trial 
participants 
4a CONSORT 2010: Eligibility criteria for participants 46 (98%) 1 (2%) 0 (0%) - 




















































































































Table 2 ( continued ) 
Item b CONSORT 2010 Items, CONSORT-ROUTINE modifications, and new 
CONSORT-ROUTINE items 














Modified CONSORT-ROUTINE: Eligibility criteria for trial 
participants, including information on how to access the list of 
codes and algorithms used to identify eligible participants, 
information on accuracy and completeness of data used to 
ascertain eligibility, and methods used to validate accuracy and 
completeness (e.g., monitoring, adjudication), if applicable 
0 (0%) 4 (9%) 19 (40%) 24 
(51%) 
ROUTINE-4 New CONSORT-ROUTINE: Describe whether and how consent 
was obtained 
33 (70%) 5 (11%) 9 (19%) - 
Outcomes 6a CONSORT 2010: Completely defined pre-specified primary and 
secondary outcome measures, including how and when they were 
assessed 
45 (96%) 2 (4%) 0 (0%) - 
Modified CONSORT-ROUTINE: Completely defined pre-specified 
primary and secondary outcome measures, including how and 
when they were ascertained and the cohort or routinely collected 
database(s) used to ascertain each outcome 
35 (75%) 2 (4%) 0 (0%) 10 
(21%) 
ROUTINE-5 New CONSORT-ROUTINE: Information on how to access the list 
of codes and algorithms used to define or derive the outcomes 
from the cohort or routinely collected database(s) used to conduct 
the trial, information on accuracy and completeness of outcome 
variables, and methods used to validate accuracy and 
completeness (e.g., monitoring, adjudication), if applicable 
3 (6%) 15 
(32%) 




9 CONSORT 2010: Mechanism used to implement the random 
allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until 
interventions were assigned c 
Modified CONSORT-ROUTINE: Mechanism used to implement the 
random allocation sequence (such as embedding an automated 
randomiser within the cohort or routinely collected database(s)), 
describing any steps taken to conceal the sequence until 
interventions were assigned c 
26 (55%) 3 (6%) 18 (38%) - 
Results 
Participant 
flow (a diagram 
is strongly 
recommended) 
13a CONSORT 2010: For each group, the numbers of participants 
who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
46 (98%) 1 (2%) 0 (0%) - 




















































































































Table 2 ( continued ) 
Item b CONSORT 2010 Items, CONSORT-ROUTINE modifications, and new 
CONSORT-ROUTINE items 














Modified CONSORT-ROUTINE: For each group, the number of 
participants in the cohort or routinely collected database(s) used 
to conduct the trial and the numbers screened for eligibility, 
randomly assigned, offered and accepted interventions (e.g., 
cohort multiple RCTs), received intended treatment, and analysed 
for the primary outcome 
2 (4%) 5 (11%) 16 (34%) 24 
(51%) 
Discussion 
Interpretation 22 CONSORT 2010: Interpretation consistent with results, balancing 
benefits and harms, and considering other relevant evidence 
46 (98%) 1 (2%) 0 (0%) - 
Modified CONSORT-ROUTINE: Interpretation consistent with 
results, balancing benefits and harms, and considering other 
relevant evidence, including the implications of using data that 
were not collected to answer the trial research questions 
12 (25%) 8 (17%) 27 (57%) - 
Other 
information 
Funding 25 CONSORT 2010: Sources of funding and other support (such as 
supply of drugs), role of funders 
32 (68%) 5 (11%) 10 (21%) - 
Modified CONSORT-ROUTINE: Sources of funding and other 
support for both the trial and the cohort or routinely collected 
database(s), role of funders 
3 (6%) 25 
(53%) 
19 (40%) - 
a For modified items, modifications are shown in bold. For those items, only portion modified was evaluated. Not all items will be applicable to all trials. 
b Item numbers reflect numbers in original 2010 CONSORT checklist that were modified or new items. New items are designated by “ROUTINE”
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(46 of 47; 98%). Most studies also adequately reported the
details on how and when registries were used for each of
the outcomes (35 of 47; 75%). 
When the registry was used to identify eligible patients
to facilitate trial recruitment, the codes and algorithms
used were never adequately reported (0 of 23 where ap-
plicable [0%]). Information on the embedding of a ran-
dom allocation sequence within the registry would have
been assessable in only about one half of the publica-
tions (adequately reported in 26 out of 47 trials; 55%). Al-
though the participant flow was almost perfectly reported
for the CONSORT 2010 item, additional details from the
CONSORT-ROUTINE extension were almost never ade-
quately reported (2 of 23 where applicable [9%]); meaning
that it was difficult to determine which participants from
the registry were randomized, excluded, lost to follow up
or included in the analysis. The implications of using a co-
hort or routinely collected data in the RCT and discussing
its strengths and limitations, was adequately reported in
a quarter of our sample, making it difficult to ascertain
whether the authors considered and addressed such impli-
cations when designing and interpreting their trial (12 of
47, 25%). Details of funding for the registry were ade-
quately reported in 6% (3 of 47) of the publications, leav-Please cite this article as: K.A. Mc Cord et al., Reporting transparency and c
registries was often inadequate and hindered the interpretation of results, Journaling it often unclear if the funders of the registry had any
involvement in the trial design and interpretation. 
Reporting of the CONSORT 2010 items was overall
similar in primary and secondary publications (see Ap-
pendix 4). 
New Items in CONSORT-ROUTINE 
Of the five new CONSORT-ROUTINE items, two were
adequately reported in more than half of the 47 trial re-
ports, although the reporting was insufficient for the other
three items ( Table 2 ). 
The criteria defining eligibility for participation in the
registry were adequately reported in only 32% of the pub-
lications (15 of 47). Users of these publications would
not have had sufficient information on data linkage (ad-
equately reported in 4 of 47 trials, 8%) and information
on the codes and algorithms used for outcome measure-
ment and their accuracy and completeness was adequately
provided for only 3 reports (out of 39 where applicable;
8%). 
4. Discussion 
Our assessment of the reporting of 47 systematically
identified articles on RCTs that used registries showed thatompleteness in Trials: Paper 2 - reporting of randomised trials using 
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key information addressed by established CONSORT 2010
items was often adequately reported, Although crucial de-
tails that are increasingly recognized as being essential for
trials using registry data were lacking for most of them.
Critical information on data linkage and data quality were
typically missing. 
Issues of data validation and endpoint adjudication, Al-
though often being considered the Achilles heel of using
routinely collected data [5–22] , were not adequately re-
ported in the trials that we assessed. Additionally, issues
of applicability and generalizability were difficult to in-
terpret because the eligibility for inclusion in the registry
was rarely reported. Details on linkage methodology be-
tween registries or other routinely collected data, which
can add errors and biases due to incomplete or incorrect
matching of the participant, were pervasively difficult to
ascertain. 
Because the interpretation of the strengths and limita-
tions of RCTs is evaluated through all of these items, this
level of improper reporting introduces clearly avoidable
waste of such research, some of them may render this trial
research useless and the related investments and resources
might be research waste [23] . These findings highlight the
importance of developing a reporting guideline for RCTs
using routinely collected data to guide authors in report-
ing the critical items required for appropriate assessment
and potential replication of these novel trials, which until
now had not existed. No standards were available to the
authors, reviewers and editors of the trial publications that
we assessed. 
Our results for the CONSORT 2010 items are consistent
with previously published data on the insufficient quality
of reporting in biomedicine, although the reporting quality
of the CONSORT 2010 items in our sample was markedly
higher than previously published [11-24 , 25] . For example,
in a review of pre-post CONSORT extension for Abstracts
[25] , seven items had an adherence below 50% for 164
RCTs published in the after years of the extension being
published (post-CONSORT-A) [25] . Nevertheless, a trend
of improvement was seen between 2005 and 2016 which
may indicate a continued improvement in the reporting of
CONSORT items [25] . Across the CONSORT 2010 items,
“allocation concealment mechanism” was the one that was
most frequently not well reported (adequate in 55% of tri-
als), which is still an improvement compared to a propor-
tion of 25% found in an analysis of trial reports published
before CONSORT 2011 [26] . 
This is the first evaluation of registry-specific reporting
in RCTs, but the findings are comparable to those observed
in non-randomized studies [24] : the use of routinely col-
lected data was often described in titles or abstracts (85%),
and the characteristics of the data source and settings were
adequately reported in half of the studies (51%). However,
details on the coding pertinent to the selection of partic-
ipants and ascertainment of outcomes (0% and 8% ade-
quate) as well as aspects pertaining to data source linkagePlease cite this article as: K.A. Mc Cord et al., Reporting transparency and 
registries was often inadequate and hindered the interpretation of results, Journal(8% adequate) were not sufficiently reported in most stud-
ies. 
Furthermore, our findings were consistent with those of
studies on trials conducted using other routinely collected
data (EHR [14] or administrative data) [15] . For all three
data sources, the reporting of elements related to the use of
routinely collected data (the CONSORT-ROUTINE items)
were overall inadequately reported, although trials using
registry data were overall better reported than the other
sources. 
There are a several limitations with our study. 
Firstly, we performed an assessment of the reporting
quality, which is to some degree subjective. We aimed
to address this by using prespecified criteria and we per-
formed all extractions systematically and in duplicate. 
Secondly, the search strategy was developed for a dif-
ferent scope than that of this specific study, which may
have rendered a sample less representative. By identifying
RCTs using search terms related to registries in the En-
glish literature to inform a reporting guideline, our sample
was not an exhaustive review of the entire literature, and
we did not aim to provide a comprehensive overview of
all published trials using registries. Thus, the distribution
of the characteristics of RCTs using registries (such as
geographical location and medical specialty) may not be
fully representative of the research landscape in this field.
However, we have no reason to believe that we have sub-
stantially underestimated the quality of reporting and that
our conclusions would be different with a different sam-
pling strategy. The identification of the trials used for this
sample depended on information in the abstract or in key-
words which probably has led to an overestimation of the
reporting quality for this item (item 1b; this item would
almost always be reported in our sample or we would have
identified the trial only via keywords). To determine over-
all eligibility, we had to know that a registry was used
– this implies an overestimation of the reporting quality
overall for any item that relates to the general use of a
registry. 
Thirdly, a third of our sample included publications that
were not the main publications, and we did not consider al-
ternative/primary publications even when authors reported
that additional information could be found elsewhere. We
believe that the minimum reporting standards as developed
in CONSORT-ROUTINE should be accessible in all pri-
mary and secondary RCT publications for adequate report-
ing. 
Fourthly, we did not pose a distinction in the types of
RCTs using registries included. For example, there may
well be a difference in the quality of reporting of a RCT
that used a registry to assess a secondary outcome (a
trial supported by registry data) and a registry-based RCT,
where the trial is fully planned and embedded within the
infrastructure of a registry. It is possible that these two
types of registry utilizations would be subject to different
levels of reporting quality. completeness in Trials: Paper 2 - reporting of randomised trials using 
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In conclusion, our assessment of the reporting trans-
parency and completeness indicates that RCTs conducted
using registries are currently inadequately reported for sev-
eral critical details. The implications are that the user of
such a trial report would not have sufficient information
to replicate the trial, assess potential biases or to apply
the trial findings. The new CONSORT-ROUTINE provides
guidance to improve reporting of these types of trials and
highlights the need for its uptake by all involved stakehold-
ers, including authors, peer-reviewers and journals editors.
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